pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 42 Non-oncology: 26
Oncology: 16
Under Consideration for Negotiation 12 Non-oncology: 9
Oncology: 3
Completed Negotiations 794 With Letter of Intent: 687
Without agreement: 107
Negotiations That Were Not Pursued 108

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Blincyto Amgen Canada Inc. Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR)
Voydeya Alexion Pharma GmbH Paroxysmal nocturnal hemoglobinuria (PNH)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Uplizna Horizon Therapeutics Canada Neuromyelitis optica spectrum disorder (NMOSD)
Wainua AstraZeneca Canada Inc. Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Cosentyx Novartis Pharmaceuticals Canada Inc. Hidradenitis Suppurativa
Velsipity Pfizer Canada ULC Ulcerative Colitis
Alecensaro Hoffmann-La Roche Ltd. Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Keytruda Merck Canada Inc. For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
Enhertu (concluded with pTAP LOI) AstraZeneca Canada Inc. As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks